The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes

Seminars in Vascular Medicine

Volumn 3, Issue 2, 2003, Pages 139-146

  Haas, Sylvia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute coronary syndromes; Heparin; Hirudin; Low molecular weight heparins; Pentasaccharide; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9A; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSAMINE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN BINDING PROTEIN; HEPARIN COFACTOR II; HEPARIN LYASE; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PADGEM PROTEIN; PENTASACCHARIDE; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; TICLOPIDINE; UNINDEXED DRUG; WARFARIN;

ALLERGIC REACTION; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BINDING SITE; BLEEDING; BOLUS INJECTION; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY STENT; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; MORTALITY; OUTCOMES RESEARCH; PATIENT MONITORING; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDIN THERAPY; HUMANS; MYOCARDIAL INFARCTION; POLYSACCHARIDES; VENOUS THROMBOSIS;

EID: 0041473374     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40672     Document Type: Article

References (32)

1. Rosenberg RD, Damu PS, The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973;248:6490-6505
2. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976;69:570-577
3. Lindahl U, Backstrom G, Thunberg L. The antithrombin-binding sequence in heparin: identification of an essential 6-O-sulfate group. J Biol Chem 1983;25:9826-9830
4. Gallo R, Chesebro JH, Badimon JJ. Treatment of unstable angina: role of antithrombotic therapy. Thromb Res 1999;95: V15-V31
5. Jeske W, Fareed J. In vitro studies on the biochemistry and pharmacology of low molecular weight heparin. Semin Thromb Hemost 1999;25:27-34
6. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992;267:12528-12538
7. Haas S. Prevention of venous thromboembolism: recommendations based on the International Consensus and the American College of Chest Physicians Sixth Consensus Conference on antithrombotic therapy. Clin Appl Thromb Hemost 2001;7:171-177
8. Haas S. Treatment of deep venous thrombosis and pulmonary embolism. Med Clin North Am 1998;82:495-510
9. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable angina. J Am Coll Cardiol 1994;24:39-45
10. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568
11. Swahn E, Wallentin L, for the FRISC Study Group. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol 1997;80 (suppl 5A):25E-29E
12. Klein W, Buchwald A, Hillis SE, et al., for the FRIC Investigators. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable Coronary Artery Disease Study (FRIC). Circulation 1997;96:61-68
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular-weight heparin weight unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452
14. Goodman S, Bigonzi F, Radley D, Le Louer V, Gosset F, Cohen M, for the ESSENCE Group. One-year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction (abstract). Eur Heart J 1998;50:P477
15. Antman EM, McCabe CH, Gurfinkel EP, et al., for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601
16. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-1942
17. Zidar JP. Low-molecular weight heparins in coronary stenting (the ENTICES trial). Enoxaparin and ticolpidine after elective stenting. Am J Cardiol 1998;82:29L-32L
18. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613
19. Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-625
20. Lassen MR, Bauer KA, Eriksson BI, Turpie AG, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee postoperative fondaparinux versus preoperative enoxyparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-1720
21. Turpie AG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxyparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726
22. Bauer KA, Eriksson BA, Lassen MR, Turpie AG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study (PENTAMAKS). Fondaparinux compared with enoxyparin for the prevention of venous thromboembolism after elective knee surgery. N Engl J Med 2001;345:1305-1310
23. Eriksson BI, Bauer KA, Lassen MR, Turpie AG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study (Penthifra). Fondaparinux compared with enoxyparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304
24. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enocyparin for prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840
25. Topol EJ, Fuster V, Harrington DJ, et al. Recombinant hirudin for unstable angina pectoris: a multicentre, randomized, angiographic trial. Circulation 1994;89:1557-1559
26. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes N Engl J Med 1996;335:775-782
27. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;96:769-777
28. OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999,353:429-438
29. Eriksson BI, Wille-Jörgensen P, Kälebo P, Mouret P, et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335
30. Mola M, Schiele F, Walker, et al. Treatment of acute deep vein thrombosis (DVT) by subcutaneous r-hirudin (HBW 023): a multi-centre study. Thromb Haemost 1995;83:1456
31. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993;70:386
32. Schiele F, Vuillemenot A, Kramarz P, et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:558